Intrinsic Value of S&P & Nasdaq Contact Us

Penumbra, Inc. PEN NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score
67/100
3/7 Pass
SharesGrow Intrinsic Value
$304.88
-8.2%
Analyst Price Target
$371.92
+12%

Penumbra, Inc. (PEN) — Analyst outlook / Analyst consensus target is. Based on 22 analyst ratings, the consensus is bullish — 9 Buy, 13 Hold.

The consensus price target is $371.92 (low: $349.00, high: $388.00), representing an upside of 12% from the current price $332.17.

Analysts estimate Earnings Per Share (EPS) of $2.79 and revenue of $1.19B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $0.36 vs est $2.79 (missed -87.1%). 2025: actual $4.57 vs est $3.79 (beat +20.7%). Analyst accuracy: 0%.

PEN Stock — 12-Month Price Forecast

$371.92
▲ +11.97% Upside
Average Price Target
Based on 22 Wall Street analysts offering 12-month price targets for Penumbra, Inc., the average price target is $371.92, with a high forecast of $388.00, and a low forecast of $349.00.
The average price target represents a +11.97% change from the last price of $332.17.
Highest Price Target
$388.00
Average Price Target
$371.92
Lowest Price Target
$349.00

PEN Analyst Ratings

Hold
22
Ratings
9 Buy
13 Hold
Based on 22 analysts giving stock ratings to Penumbra, Inc. in the past 3 months
Rating breakdown
Buy
9 41%
Hold
13 59%
41%
Buy
9 analysts
59%
Hold
13 analysts
0%
Sell
0 analysts

EPS Estimates — PEN

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual $0.36 vs Est $2.79 ▼ 676.0% off
2025 Actual $4.57 vs Est $3.79 ▲ 17.2% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.

Revenue Estimates — PEN

99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $1.195B vs Est $1.191B ▲ 0.3% off
2025 Actual $1.404B vs Est $1.380B ▲ 1.7% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message